Abstract: A suspension includes an ophthalmic active ingredient suspended in a formulation vehicle including a suspending agent and a non-ionic cellulose derivative. The ophthalmic active agent is present as particles having DV90 < 5 µm and Dv50< 1 µm. The suspension may be administered to a patient for treating an ophthalmic inflammatory condition.

Abstract: A suspension includes an ophthalmic active ingredient suspended in a formulation vehicle including a suspending agent and a non-ionic cellulose derivative. The ophthalmic active agent is present as particles having Dv90<5 ?m and Dv50<1 ?m. The suspension may be administered to a patient for treating an ophthalmic inflammatory condition.

Abstract: A suspension includes an ophthalmic active ingredient suspended in a formulation vehicle including a suspending agent and a non-ionic cellulose derivative. The ophthalmic active agent is present as particles having Dv90<5 ?m and Dv50<1 ?m. The suspension may be administered to a patient for treating an ophthalmic inflammatory condition.

Abstract: A suspension includes an ophthalmic active ingredient suspended in a formulation vehicle including a suspending agent and a non-ionic cellulose derivative. The ophthalmic active agent is present as particles having Dv90<5 ?m and Dv50<1 ?m. The suspension may be administered to a patient for treating an ophthalmic inflammatory condition.

Abstract: A suspension includes an ophthalmic active ingredient suspended in a formulation vehicle including a suspending agent and a non-ionic cellulose derivative. The ophthalmic active agent is present as particles having Dv90<5 ?m and Dv50<1 ?m. The suspension may be administered to a patient for treating an ophthalmic inflammatory condition.

Abstract: A suspension comprising a mixture of omega-3 fatty acids suspended in a formulation vehicle. The formulation vehicle comprises a lightly cross-linked carboxy-containing polymer and a concentration of ionic salt components to provide the suspension with a calculated ionic strength of less than 0.1. The suspension has the following rheological properties, G?>G? and a suspension yield value of greater than 1 Pa. Also, upon addition of 30 mL of the suspension to a volume of 6 mL to 12 mL of simulated tear fluid, the resulting tear mixture transitions to a liquid form wherein, G?>G? and the tear mixture has a yield value of less than 0.1 Pa.

Abstract: A suspension comprising a mixture of wax esters suspended in a formulation vehicle. The formulation vehicle comprises a lightly cross-linked carboxy-containing polymer and a concentration of ionic salt components to provide the suspension with a calculated ionic strength of less than 0.1. The suspension has the following rheological properties, (T>G? and a suspension yield value of greater than 1 Pa. Also, upon addition of 30 mL of the suspension to a volume of 6 mL to 12 mL of simulated tear fluid, the resulting tear mixture transitions to a liquid form wherein, G?>G? and the tear mixture has a yield value of less than 0.1 Pa.

Abstract: A packaging system for the storage of an ionic, hydrogel contact lens employs an aqueous packaging solution including a phosphorylcholine polymer. Preferably, the solution has an osmolality of at least about 200 mOsm/kg, a pH of about 6 to about 8 and is heat sterilized.

Abstract: A suspension comprising an ophthalmic active that has a solubility in water at 25° C. and a pH of 7 of less than 0.1 times the concentration of the active in mg/mL in the suspension, the ophthalmic active suspended in a formulation vehicle. The formulation vehicle comprises a lightly cross-linked carboxy-containing polymer and a concentration of ionic salt components to provide the suspension with a calculated ionic strength of less than 0.1. The suspension has the following rheological properties, G?>G? and a suspension yield value of greater than 1 Pa. Also, upon addition of 30 mL of the suspension to a volume of 6 mL to 12 mL of simulated tear fluid, the resulting tear mixture transitions to a liquid form wherein, G?>G? and the tear mixture has a yield value of less than 0.1 Pa.

Abstract: A pharmaceutical composition comprises a polyethylene glycol having a molecular weight in the range from about 1,000 to about 10,000, and a water-soluble cellulose derivative having a molecular weight in the range from about 50,000 to 120,000. The composition can further comprise boric acid and/or phosphate, a non-ionic surfactant, and/or an ophthalmic therapeutic agent. The composition is effective in treating, controlling, ameliorating, or reversing one or more conditions or symptoms of dry eye.

Abstract: An aqueous ophthalmic composition comprising loteprednol etabonate, and polyacryclic acid. The composition has a viscosity in the range from about 300 cp to about 1500 cp, and a total concentration of cations of less than about 50 mM. The ophthalmic composition is used to treat patients suffering from allergic conjunctivitis, and includes instructing a person suffering from ocular itching resulting from allergic conjunctivitis to administer once or twice daily in the form of one or more eye drops the aqueous ophthalmic composition described.

Abstract: A pharmaceutical formulation comprises a pharmaceutically acceptable preservative and a material selected from the group consisting of D-glucose, sucrose, maltose, D-mannose, trehalose, glutamic acid, mixtures thereof, and combinations thereof, wherein the formulation has enhanced preservative efficacy against spore-forming microorganisms. The formulation can further comprise boric acid and/or phosphate. A method for enhancing the preservative efficacy of a pharmaceutical formulation against spore-forming microorganisms, comprising adding a pharmaceutically acceptable preservative, and a material selected from the group consisting of D-glucose, sucrose, maltose, D-mannose, trehalose, glutamic acid, mixtures thereof, and combinations thereof, to the pharmaceutical formulation. The formulation optionally includes an active agent for treating or controlling a disease or disorder of the eye. The formulation may be used to treat, clean, disinfect, store, wet, or rewet contact lenses.

Abstract: A pharmaceutical composition includes at least one pharmaceutical component and at least one water-immiscible material. The pharmaceutical component is more soluble in the water-immiscible material than in water. The pharmaceutical composition is suitable for ocular administration.

Abstract: An aqueous ophthalmic composition comprises a carboxy-containing polyanionic polymer that has a viscosity in the range from about 300 cp to about 1500 cp outside the eye and a total concentration of cations of less than about 50 mM, wherein the viscosity of the composition does not increase when the composition comes into contact with surface ocular fluid.

Abstract: An multifunctional ophthalmic composition includes a nonionic oxygen-containing polymer and a surfactant. The composition can be used to treat or control ophthalmic diseases, conditions, or disorders. The composition can be a drug delivery vehicle for medicaments having low solubility in water.

Abstract: A pharmaceutical composition includes at least one pharmaceutical component having a low aqueous solubility and at least one non-aqueous water-miscible material. Such a pharmaceutical composition is useful in providing a therapeutically meaningful amount of such pharmaceutical component at a target tissue. The pharmaceutical composition is particularly suitable for administration to or into an ocular environment to treat or control an ocular disease, disorder, or condition.

Abstract: A packaging system for the storage of an ionic, hydrogel contact lens employs an aqueous packaging solution including a phosphorylcholine polymer. Preferably, the solution has an osmolality of at least about 200 mOsm/kg, a pH of about 6 to about 8 and is heat sterilized.

Abstract: This invention is directed to high molecular weight water-soluble polymers comprised of zwitterionic, nonionic and cationic or anionic monomer units, and to the use of these polymers in papermaking processes.

Abstract: This invention is directed to high molecular weight water-soluble polymers comprised of zwitterionic, nonionic and cationic or anionic monomer units, and to the use of these polymers in papermaking processes.

Abstract: Controlled release pharmaceutical compositions comprising tolterodine and a polymer-based release-controlling component and processes for preparing such compositions are provided. The compositions are useful in the treatment of overactive bladder and similar conditions.